英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

perfuse    
vt. 洒遍,撒满,撒布

洒遍,撒满,撒布

perfuse
v 1: force a fluid through (a body part or tissue); "perfuse a
liver with a salt solution"
2: cause to spread or flush or flood through, over, or across;
"The sky was suffused with a warm pink color" [synonym:
{suffuse}, {perfuse}]

Perfuse \Per*fuse"\ (p[~e]r*f[=u]z"), v. t. [imp. & p. p.
{Perfused} (p[~e]r*f[=u]zd"); p. pr. & vb. n. {Perfusing}.]
[L. perfusus, p. p. of perfundere to pour over; per fundere
to pour.]
1. To suffuse; to fill full or to excess. --Harvey.
[1913 Webster]

2. To pass a liquid through or over; as, the isolated kidney
was perfused with saline solution.
[PJC]

3. (Surgery) To pass (a liquid) through an organ.
[PJC]


请选择你想看的字典辞典:
单词字典翻译
perfuse查看 perfuse 在百度字典中的解释百度英翻中〔查看〕
perfuse查看 perfuse 在Google字典中的解释Google英翻中〔查看〕
perfuse查看 perfuse 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Treatment for Advanced CSCC | LIBTAYO® (cemiplimab-rwlc)
    Learn about LIBTAYO® (cemiplimab-rwlc) for the treatment of advanced CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • Libtayo® (cemiplimab) now approved in Canada for the . . .
    Fourth Canadian approval of Libtayo in difficult-to-treat cancers MISSISSAUGA, ON, March 25, 2022 CNW Telbec - Today sanofi-aventis Canada Inc (Sanofi) announced the approval of Libtayo ® (cemiplimab) for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC
    LIBTAYO® (cemiplimab-rwlc) is a 1L treatment of advanced NSCLC in certain adults as a monotherapy with PD-L1 expression ≥ 50% and no EGFR, ALK, ROS1 aberrations, and in combination with platinum-based chemotherapy with no EGFR, ALK, ROS1 aberrations Review Important Safety Information and full Prescribing Information
  • Cemiplimab: Side Effects, Uses, Dosage, Interactions, Warnings
    Cemiplimab is a cancer medicine that helps your immune system fight certain cancers What it treats Advanced or hard-to-treat: Some skin cancers (certain squamous cell and basal cell skin cancers) Some types of lung cancer (non–small cell lung cancer) Cemiplimab is available under the following different brand names: Libtayo, cemiplimab-rwlc
  • Covering Every FDA Oncology Approval From October 2025
    FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma The FDA has approved Libtayo (cemiplimab-rwlc) for adjuvant treatment in adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation This approval was based on the C-POST trial, which included 415 patients at high risk of recurrence
  • NCCN Guidelines recommend cemiplimab-rwlc - Targeted Onc
    LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival . . .
    Regeneron has shared positive, long-term overall survival (OS) data from the Phase III EMPOWER-Lung 3 clinical trial (NCT03409614), which assessed Libtayo (cemiplimab) along with platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with
  • Overview | Cemiplimab with platinum-based chemotherapy for . . .
    Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults





中文字典-英文字典  2005-2009